Drugs /

telisotuzumab vedotin

Back to Drugs List

Overview

Generic Name(s):
telisotuzumab vedotin
NCI Definition [1]:
An antibody-drug conjugate (ADC) composed of telisotuzumab, a monoclonal antibody against the tumor-associated antigen (TAA) and proto-oncogene, c-Met receptor tyrosine kinase (c-Met; MET; hepatocyte growth factor receptor; HGFR) conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline (vc) peptide linker (vc-MMAE; vedotin), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of telisotuzumab vedotin targets and binds to c-Met expressed on tumor cells. Upon binding, internalization and enzymatic cleavage, the cytotoxic agent MMAE is released into the cytosol. MMAE binds to tubulin and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. This kills the c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.

Clinical Trials

View Clinical Trials for telisotuzumab vedotin

Telisotuzumab vedotin has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating telisotuzumab vedotin, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open).

EGFR Exon 19 Deletion, EGFR L858R, and MET Expression are the most frequent biomarker inclusion criteria for telisotuzumab vedotin clinical trials.

Non-small cell lung carcinoma and non-squamous non-small cell lung carcinoma are the most common diseases being investigated in telisotuzumab vedotin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Telisotuzumab Vedotin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating telisotuzumab vedotin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
abbv399, abbv 399, abt-700-vcmmae, abbv-399, antibody-drug conjugate abbv-399
Drug Target(s) [2]:
MET
NCIT ID [1]:
C118571

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.